Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23875143 | 1.00 | CES2 (0.40) | CES2HSD17B10ALOX15TSHRALDH1A1 | |
| SCHEMBL25733878 | 1.00 | CES2 (0.40) | CES2HSD17B10ALOX15TSHRALDH1A1 | |
| SCHEMBL2287377 | 1.00 | CES2 (0.40) | CES2HSD17B10ALOX15TSHRALDH1A1 | |
| SCHEMBL22266204 | 1.00 | CES2 (0.40) | CES2HSD17B10ALOX15TSHRALDH1A1 | |
| SCHEMBL2241590 | 0.95 | — | — | |
| SCHEMBL22266462 | 0.91 | CES2 (0.47) | CES2HSD17B10TSHRALDH1A1MEN1 | |
| SCHEMBL22325195 | 0.89 | CES2 (0.36) | CES2HSD17B10ALOX15TSHRALDH1A1 | |
| SCHEMBL6668639 | 0.89 | CES2 (0.36) | CES2HSD17B10ALOX15TSHRALDH1A1 | |
| SCHEMBL30661132 | 0.89 | CES2 (0.36) | CES2HSD17B10ALOX15TSHRALDH1A1 | |
| SCHEMBL6712841 | 0.89 | CES2 (0.36) | CES2HSD17B10ALOX15TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2183220-A1 | BIODEGRADABLE SOLVENTS FOR THE CHEMICAL INDUSTRY | Dublin City University (IE) | 2010-05-12 | — | — | EP | claimed |
| WO-2009024607-A1 | BIODEGRADABLE SOLVENTS FOR THE CHEMICAL INDUSTRY | DUBLIN CITY UNIVERSITY (IE) | 2009-02-26 | — | — | WO | claimed |
| WO-2023205892-A1 | CDK INHIBITORS AND PHARMACEUTICAL USES THEREOF | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023192873-A1 | MACROCYCLIC IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-10-05 | — | — | WO | disclosed |
| US-11529394-B2 | Polypeptide conjugates and methods of uses | BEIJING QL BIOPHARMACEUTICAL CO., LTD. (CN) | 2022-12-20 | — | — | US | disclosed |
| US-20220396563-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | ACHILLION PHARMACEUTICALS, INC. | 2022-12-15 | — | — | US | disclosed |
| EP-3065767-B1 | GIP-GLP-1 DUAL AGONIST COMPOUNDS AND METHODS | ZEALAND PHARMA AS (DK) | 2020-12-30 | — | — | EP | disclosed |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | ARVINAS OPERATIONS, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20180140673-A1 | FGF21 Derivatives and Uses Thereof | NOVO NORDISK A/S (DK) | 2018-05-24 | — | — | US | disclosed |
| EP-2183220-B1 | BIODEGRADABLE SOLVENTS FOR THE CHEMICAL INDUSTRY | UNIV DUBLIN CITY (IE) | 2016-11-09 | — | — | EP | disclosed |
| US-8541598-B2 | Biodegradable solvents for the chemical industry | DUBLIN CITY UNIVERSITY (IE) | 2013-09-24 | — | — | US | disclosed |
| US-20110201824-A1 | BIODEGRADABLE SOLVENTS FOR THE CHEMICAL INDUSTRY | DUBLIN CITY UNIVERSITY (IE) | 2011-08-18 | — | — | US | disclosed |
| EP-2183220-A1 | BIODEGRADABLE SOLVENTS FOR THE CHEMICAL INDUSTRY | Dublin City University (IE) | 2010-05-12 | — | — | EP | disclosed |
| US-20100004137-A1 | Characterization of biochips containing self-assembled monolayers | UNIVERSITY OF CHICAGO, THE | 2010-01-07 | — | — | US | disclosed |
| WO-2009024607-A1 | BIODEGRADABLE SOLVENTS FOR THE CHEMICAL INDUSTRY | DUBLIN CITY UNIVERSITY (IE) | 2009-02-26 | — | — | WO | disclosed |
| US-4386935-A | Process for producing discharge reserve prints on textile materials with amino-azo-benzene dyes | CASSELLA AKTIENGESELLSCHAFT (DE) | 1983-06-07 | — | — | US | disclosed |
| EP-0051261-A1 | Process for the production of discharge-resist prints on textile materials | CASSELLA Aktiengesellschaft (DE) | 1982-05-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11529394-B2 | Polypeptide conjugates and methods of uses | GLP1R, GIPR, IAPP | CES2 1562/4885HSD17B10 2522/4885ALOX15 3966/4885 |
| US-20180140673-A1 | FGF21 Derivatives and Uses Thereof | FGF2, FGFR1, FGF1 | CES2 2735/4885HSD17B10 306/4885ALOX15 3100/4885 |
| US-20110201824-A1 | BIODEGRADABLE SOLVENTS FOR THE CHEMICAL INDUSTRY | TIMM9, B2M, TIMM44 | CES2 1170/4885HSD17B10 1280/4885ALOX15 1401/4885 |
| US-20220396563-A1 | ARYL, HETEROARYL, AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERS | CFD, TFPI, CFH | CES2 3695/4885HSD17B10 1063/4885ALOX15 123/4885 |
| US-10723717-B2 | Compounds and methods for the targeted degradation of rapidly accelerated fibrosarcoma polypeptides | CRBN, ARAF, VHL | CES2 3556/4885HSD17B10 3903/4885ALOX15 4067/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.